Tekla Capital Management LLC Cytom X Therapeutics, Inc. Transaction History
Tekla Capital Management LLC
- $2.53 Billion
- Q2 2023
Shares
3 transactions
Others Institutions Holding CTMX
# of Institutions
76Shares Held
50.2MCall Options Held
22.3KPut Options Held
22.9K-
Tang Capital Management LLC San Diego, CA7.79MShares$9.35 Million1.16% of portfolio
-
Janus Henderson Group PLC London, X06.3MShares$7.56 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$6.27 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$5.87 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$3.6 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $79.1M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...